Valganciclovir
- Generic Name
- Valganciclovir
- Brand Names
- Valcyte
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N6O5
- CAS Number
- 175865-60-8
- Unique Ingredient Identifier
- GCU97FKN3R
- Background
Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
- Indication
Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
- Associated Conditions
- Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
- Conditions
- Cytomegalovirus (CMV)Kidney Transplant; ComplicationsKidney Diseases
- Interventions
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 360
- Registration Number
- NCT06798909
- Locations
- 🇺🇸
University of California, San Francisco School of Medicine, San Francisco, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
Phase 1 Study of GEN2 in Patients with Advanced Solid Tumors
- Conditions
- Solid Tumor, Adult
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- GenVivo, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06391918
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
🇺🇸University of Southern California-Keck School of Medicine, Los Angeles, California, United States
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
- Conditions
- Cytomegalovirus Infection
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 80
- Registration Number
- NCT06334497
- Locations
- 🇫🇷
Hôpital Necker Enfants Malades, Paris, France
Maribavir Vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
- Conditions
- CMVTransplant Complication
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 70
- Registration Number
- NCT06034925
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
CMV Immunity Monitoring in Lung Transplant Recipients
- Conditions
- Lung Transplant; Complications
- Interventions
- Device: Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)Diagnostic Test: Donor-Derived Cell-Free DNA (dd-cfDNA) Assay
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 50
- Registration Number
- NCT05708755
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Piedmont Healthcare
- Target Recruit Count
- 37
- Registration Number
- NCT05238220
- Locations
- 🇺🇸
Piedmont Atlanta Hospital, Atlanta, Georgia, United States
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
- Conditions
- Nasopharyngeal CarcinomaEBV-Related Gastric CarcinomaEBV-Related LeiomyosarcomaEBV Related CarcinomaEBV-Related Sarcoma
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05166577
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Letermovir for CMV Prevention After Lung Transplantation
- Conditions
- Lung TransplantCMV
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Fernanda P Silveira, MD, MS
- Target Recruit Count
- 16
- Registration Number
- NCT05041426
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Laureate Institute for Brain Research, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04724447
- Locations
- 🇺🇸
Laureate Institute for Brain Research, Tulsa, Oklahoma, United States
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
- Conditions
- Glioblastoma Multiforme
- Interventions
- Radiation: Radiotherapy 60 GyDrug: Placebo oral tablet
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Cecilia Soderberg-Naucler
- Target Recruit Count
- 220
- Registration Number
- NCT04116411
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
🇳🇴Stavanger University Hospital, Stavanger, Norway
🇸🇪SE01 Karolinska University Hospital, Solna, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.